Liposomal doxorubicin (TLC D99, myocet) in combination with cyclophosphamide (C), vincristine (O) and prednisone (P) for aggressive non-Hodgkin's lymphomas (NHL).

被引：0
|
作者：
Levine, A
Tulpule, A
Espina, B
Buchanan, L
Africano, M
Welles, L
机构：
[1] Univ So Calif, Norris Canc Hosp, Los Angeles, CA USA
[2] Med Res, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
478P
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [41] Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis
    Lu, Bin
    Shen, Longfei
    Ma, Ying
    Qi, Jia
    Li, Yulin
    Wang, Zhihao
    Han, Lu
    Zhong, Ming
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma
    Cohen, Jonathon B.
    Switchenko, Jeffrey M.
    Koff, Jean L.
    Sinha, Rajni
    Kaufman, Jonathan L.
    Khoury, H. Jean
    Bumpers, Nassoma
    Colbert, Amanda
    Hutchison-Rzepka, Amanda
    Nastoupil, Loretta J.
    Heffner, Leonard T.
    Langston, Amelia A.
    Lechowicz, Mary Jo
    Lonial, Sagar
    Flowers, Christopher R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (04) : 539 - 546
  • [43] A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin's Lymphoma
    Cohen, Jonathon B.
    Switchenko, Jeffrey
    Koff, Jean L.
    Sinha, Rajni
    Kaufman, Jonathan L.
    Khoury, H. Jean
    Bumpers, Nassoma K.
    Colbert, Amanda
    Hutchison-Rzepka, Amanda A.
    Nastoupil, Loretta J.
    Heffner, Leonard T.
    Langston, Amelia
    Lechowicz, Mary Jo
    Lonial, Sagar
    Flowers, Christopher R.
    BLOOD, 2014, 124 (21)
  • [44] Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy
    Krol, ADG
    Berenschot, HWA
    Doekharan, D
    Henzen-Logmans, S
    van der Holt, B
    van 't Veer, MB
    RADIOTHERAPY AND ONCOLOGY, 2001, 58 (03) : 251 - 255
  • [45] TREATMENT OF ADVANCED NON-HODGKINS LYMPHOMA (NHL) WITH BLEOMYCIN (B), ADRIAMYCIN (A), CYCLOPHOSPHAMIDE (C), VINCRISTINE (O) AND PREDNISONE (P)(BACOP)
    SKARIN, A
    ROSENTHAL, D
    MOLONEY, W
    FREI, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1974, 15 (MAR): : 133 - 133
  • [46] Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255
    Lichtman, SM
    Niedzwiecki, D
    Barcos, M
    Carlisle, TL
    Cooper, MR
    Johnson, JL
    Peterson, BA
    ANNALS OF ONCOLOGY, 2000, 11 (09) : 1141 - 1146
  • [47] LONG-TERM FOLLOW-UP OF RITUXIMAB AND INFUSIONAL CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE (CDE) IN COMBINATION WITH HAART IN HIV-RELATED NON-HODGKIN'S LYMPHOMAS (NHL)
    Spina, M.
    Jaeger, U.
    Sparano, J. A.
    Talamini, R.
    Rossi, G.
    Vaccher, E.
    Tirelli, U.
    ANNALS OF ONCOLOGY, 2011, 22 : 237 - 237
  • [48] Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (cde) in Combination with HAART in HIV-Related Non-Hodgkin's Lymphomas (NHL)
    Spina, Michele
    Simonelli, Cecilia
    Vaccher, Emanuela
    Jaeger, Ulrich
    Sparano, Joseph
    Talamini, Renato
    Tirelli, Umberto
    BLOOD, 2008, 112 (11) : 522 - 522
  • [49] LONG-TERM FOLLOW-UP OF RITUXIMAB AND INFUSIONAL CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE (CDE) IN COMBINATION WITH HAART IN HIV-RELATED NON-HODGKIN'S LYMPHOMAS (NHL)
    Spina, M.
    Jaeger, U.
    Sparano, J.
    Talamini, R.
    Rossi, G.
    Vaccher, E.
    Tirelli, U.
    ANNALS OF ONCOLOGY, 2010, 21 : 351 - 351
  • [50] Long-term follow-up of rituximab and infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in combination with HAART in HIV-related non-Hodgkin's lymphomas (NHL)
    Spina, M.
    Simonelli, C.
    Vaccher, E.
    Jaeger, U.
    Sparano, J. A.
    Talamini, R.
    Tirelli, U.
    ANNALS OF ONCOLOGY, 2008, 19 : 151 - 152
12345